Drug:
Reaction: THERAPY INTERRUPTED
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26923434 |
US |
61 | 2 |
Product distribution issue, Therapy interrupted, |
||||
OZANIMOD HYDROCHLORIDE, |
||||
| 202 | 26924042 |
US |
76 | |
Therapy interrupted, Infection, |
||||
MITOMYCIN, MITOMYCIN, |
||||
| 203 | 26924133 |
US |
2 | |
Product distribution issue, Therapy interrupted, |
||||
BRENSOCATIB, |
||||
| 204 | 26924165 |
US |
2 | |
Product storage issue, Therapy interrupted, |
||||
BRENSOCATIB, |
||||
| 205 | 26924228 |
US |
2 | |
Cough, Intentional dose omission, Therapy interrupted, |
||||
BRENSOCATIB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, AMOXICILLIN AND CLAVULANATE POTASSIUM, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, ESTRADIOL, ERTAPENEM, ERTAPENEM SODIUM, FLUCONAZOLE, GABAPENTIN, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, MEMANTINE, MEMANTINE HYDROCHLORIDE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, TOBRAMYCIN, TOBRAMYCIN SOLUTION, TOBRAMYCIN SULFATE, VITAMIN C, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 206 | 26924254 |
US |
1 | |
Therapy interrupted, |
||||
BRENSOCATIB, ALBUTEROL SULFATE, ALBUTEROL, AMLODIPINE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SULFAMETHOXAZOLE AND TRIMETHOPRIM, |
||||
| 207 | 26924272 |
US |
2 | |
Therapy interrupted, |
||||
BRENSOCATIB, GLYCOPYRROLATE AND FORMOTEROL FUMARATE, MONTELUKAST SODIUM, |
||||
| 208 | 26924396 |
US |
1 | |
Product distribution issue, Therapy interrupted, |
||||
BRENSOCATIB, ACETYLCYSTEINE, ALBUTEROL SULFATE, ALBUTEROL, AMLODIPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DULOXETINE HYDROCHLORIDE, DULOXETINE, BENRALIZUMAB, MONTELUKAST, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 209 | 26924535 |
US |
2 | |
Compression fracture, Epilepsy, T-cell type acute leukaemia, Scoliosis, Musculoskeletal disorder, Therapy interrupted, Depression, Osteoporosis, Tooth fracture, Ill-defined disorder, Exposure to toxic agent, Adverse drug reaction, |
||||
ETANERCEPT, ETANERCEPT, ERGOCALCIFEROL, |
||||
| 210 | 26924904 |
EU |
2 | |
Myasthenia gravis, Therapy interrupted, Abdominal pain upper, Product availability issue, Blood glucose increased, Anxiety, Self-medication, |
||||
ZILUCOPLAN, |
||||
| 211 | 26925765 |
1 | ||
White blood cell count decreased, Therapy interrupted, |
||||
ASCIMINIB, |
||||
| 212 | 26928872 |
2 | ||
Therapy interrupted, Rash, Loss of personal independence in daily activities, Pain, |
||||
ADALIMUMAB-RYVK, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), DULOXETINE HYDROCHLORIDE, DULOXETINE, GABAPENTIN, ADALIMUMAB, LURASIDONE HYDROCHLORIDE, |
||||
| 213 | 26929090 |
84 | 2 | |
Cerebrovascular accident, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 214 | 26929328 |
72 | 1 | |
Renal disorder, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 215 | 26929329 |
85 | ||
Blood potassium increased, Pneumonia, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 216 | 26929336 |
66 | 1 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 217 | 26929414 |
57 | 2 | |
Pneumonia, Therapy interrupted, Product availability issue, |
||||
DEUTETRABENAZINE, |
||||
| 218 | 26915142 |
73 | 1 | |
Hypercapnia, Oxygen therapy, Chronic respiratory failure, Productive cough, Aphonia, Dysphonia, Therapy interrupted, Incorrect product administration duration, Device issue, Drug ineffective, |
||||
AMIKACIN, AMIKACIN, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, FEBUXOSTAT, FEBUXOSTAT TABLETS 40 MG, FEBUXOSTAT TABLETS 80 MG, EPINASTINE HYDROCHLORIDE, RIFAMPIN, ETHAMBUTOL HYDROCHLORIDE, CLARITHROMYCIN, |
||||
| 219 | 26915242 |
US |
82 | |
Therapy interrupted, Urinary tract infection, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 220 | 26915263 |
CA |
69 | |
Colitis ulcerative, Harvey-Bradshaw index increased, Diarrhoea, Pouchitis, Drug specific antibody present, Product availability issue, Inappropriate schedule of product administration, Off label use, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 221 | 26915317 |
US |
2 | |
Fall, Femur fracture, Rib fracture, Therapy interrupted, |
||||
BRENSOCATIB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ALBUTEROL SULFATE, ALBUTEROL, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, ERGOCALCIFEROL, COLCHICINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, ESTRADIOL, FAMOTIDINE, GABAPENTIN, GLIMEPIRIDE, EMPAGLIFLOZIN, LEVALBUTEROL, LEVALBUTEROL HYDROCHLORIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDICAINE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, LINACLOTIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METHYLPREDNISOLONE, MOMETASONE, PANTOPRAZOLE, ROSUVASTATIN, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, ZOLEDRONIC ACID, |
||||
| 222 | 26915336 |
US |
35 | 2 |
Seizure, Road traffic accident, Product use issue, Inappropriate schedule of product administration, Therapy interrupted, |
||||
ESLICARBAZEPINE ACETATE, |
||||
| 223 | 26915456 |
US |
70 | |
Therapy interrupted, Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 224 | 26915627 |
US |
21 | |
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 225 | 26915731 |
52 | ||
Therapy interrupted, Psoriasis, Inability to afford medication, |
||||
| 226 | 26916086 |
US |
83 | 1 |
Therapy interrupted, Product supply issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 227 | 26916349 |
US |
||
Product distribution issue, Product temperature excursion issue, Therapy interrupted, |
||||
LUSPATERCEPT, |
||||
| 228 | 26916569 |
US |
2 | |
Psoriasis, Therapy interrupted, Pain, |
||||
APREMILAST, |
||||
| 229 | 26916880 |
US |
63 | |
Therapy interrupted, Urinary retention, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 230 | 26917928 |
US |
85 | |
Malaise, Therapy interrupted, |
||||
MITOMYCIN, |
||||
| 231 | 26918049 |
US |
79 | |
Malaise, Oxygen saturation decreased, Therapy interrupted, |
||||
MITOMYCIN, |
||||
| 232 | 26918635 |
US |
1 | |
Musculoskeletal discomfort, Therapy interrupted, Product quality issue, |
||||
ICOSAPENT ETHYL, |
||||
| 233 | 26918641 |
US |
72 | 1 |
Blood triglycerides increased, Therapy interrupted, Product physical issue, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, |
||||
| 234 | 26918657 |
US |
68 | 1 |
Eructation, Therapy interrupted, Poor quality product administered, Insurance issue, Product physical issue, Product taste abnormal, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, ROSUVASTATIN, EVOLOCUMAB, |
||||
| 235 | 26918668 |
US |
81 | 1 |
Therapy interrupted, Poor quality product administered, Product odour abnormal, Product taste abnormal, Product physical issue, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, |
||||
| 236 | 26918683 |
US |
1 | |
Malaise, Therapy interrupted, Product physical issue, |
||||
ICOSAPENT ETHYL, |
||||
| 237 | 26918689 |
US |
59 | 1 |
Eructation, Flatulence, Abdominal discomfort, Underdose, Therapy interrupted, Poor quality product administered, Product physical issue, Product odour abnormal, Product taste abnormal, |
||||
ICOSAPENT ETHYL, |
||||
| 238 | 26918899 |
US |
||
Therapy interrupted, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 239 | 26919727 |
71 | 2 | |
Alanine aminotransferase increased, Therapy interrupted, |
||||
AFATINIB, AFATINIB, |
||||
| 240 | 26919748 |
|||
Product availability issue, Therapy interrupted, Road traffic accident, Back pain, Skin laceration, |
||||
ADALIMUMAB, |
||||
| 241 | 26920440 |
US |
2 | |
Rheumatoid arthritis, Therapy interrupted, Insurance issue, |
||||
CERTOLIZUMAB PEGOL, ERGOCALCIFEROL, ALENDRONATE SODIUM, AMLODIPINE BESYLATE, CICLOPIROX, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, NORGESTIMATE AND ETHINYL ESTRADIOL, MONTELUKAST SODIUM, MONTELUKAST, PREDNISONE, |
||||
| 242 | 26921060 |
US |
2 | |
Disability, Therapy interrupted, Pain, |
||||
APREMILAST, |
||||
| 243 | 26921090 |
US |
69 | |
Illness, Therapy interrupted, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 244 | 26923807 |
83 | 2 | |
Cardiac operation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 245 | 26923880 |
2 | ||
Compression fracture, Back pain, Nerve compression, Therapy interrupted, |
||||
ABALOPARATIDE, |
||||
| 246 | 26924282 |
76 | 1 | |
Gastrointestinal necrosis, Therapy interrupted, |
||||
RISANKIZUMAB-RZAA, |
||||
| 247 | 26924650 |
36 | ||
Therapy interrupted, Hyperhidrosis, Asthenia, Confusional state, Tremor, Chest pain, Palpitations, Anxiety, |
||||
BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, CLONIDINE, |
||||
| 248 | 26924808 |
68 | 2 | |
Large intestine infection, Compression fracture, Therapy interrupted, |
||||
DEUTETRABENAZINE, |
||||
| 249 | 26925102 |
76 | 2 | |
Dehydration, Diarrhoea, Blood electrolytes abnormal, Therapy interrupted, |
||||
PEMBROLIZUMAB, AXITINIB, |
||||
| 250 | 26925403 |
63 | 2 | |
Therapy interrupted, Product dose omission in error, Memory impairment, |
||||
ABALOPARATIDE, |
||||
| 251 | 26925452 |
79 | 1 | |
Oedema, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 252 | 26925594 |
54 | 2 | |
Pneumonia, Malaise, Therapy interrupted, |
||||
VENETOCLAX, |
||||
| 253 | 26909549 |
US |
1 | |
Therapy interrupted, Product temperature excursion issue, |
||||
ROPEGINTERFERON ALFA-2B, |
||||
| 254 | 26910053 |
US |
1 | |
Hip arthroplasty, Psoriatic arthropathy, Inappropriate schedule of product administration, Therapy interrupted, |
||||
APREMILAST, |
||||
| 255 | 26910054 |
US |
2 | |
Rheumatoid arthritis, Insurance issue, Loss of personal independence in daily activities, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, ETANERCEPT, HYDROXYCHLOROQUINE, |
||||
| 256 | 26910119 |
US |
2 | |
Arterial occlusive disease, Blood cholesterol increased, Therapy interrupted, |
||||
BRENSOCATIB, ALBUTEROL SULFATE, ALBUTEROL, CICLOPIROX, HYDROXYCHLOROQUINE, LEFLUNOMIDE, IPRATROPIUM BROMIDE, UPADACITINIB, PHENTERMINE HYDROCHLORIDE, LEVONORGESTREL, |
||||
| 257 | 26910223 |
US |
83 | |
Hospitalisation, Therapy interrupted, |
||||
MITOMYCIN, |
||||
| 258 | 26910465 |
US |
1 | |
Ankylosing spondylitis, Therapy interrupted, |
||||
GOLIMUMAB, |
||||
| 259 | 26910665 |
US |
68 | 1 |
Product use issue, Therapy interrupted, |
||||
| 260 | 26910806 |
US |
68 | 1 |
Condition aggravated, Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 261 | 26911060 |
US |
2 | |
Dementia, Therapy interrupted, Rash, |
||||
APREMILAST, |
||||
| 262 | 26911380 |
CA |
2 | |
Haemoglobin decreased, Off label use, Antibody test positive, Therapy interrupted, |
||||
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE, |
||||
| 263 | 26911838 |
US |
22 | |
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 264 | 26912483 |
US |
72 | |
Myocardial infarction, Therapy interrupted, Product dose omission issue, |
||||
VUTRISIRAN, VUTRISIRAN, |
||||
| 265 | 26912516 |
US |
31 | 1 |
Off label use, Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 266 | 26912880 |
US |
2 | |
Malaise, Exposure during pregnancy, Therapy interrupted, |
||||
ASFOTASE ALFA, |
||||
| 267 | 26913224 |
|||
Therapy interrupted, Condition aggravated, |
||||
BENRALIZUMAB, |
||||
| 268 | 26913342 |
US |
||
Asthma, Condition aggravated, Product ineffective, Therapy interrupted, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 269 | 26913391 |
2 | ||
Surgery, Therapy interrupted, |
||||
SELPERCATINIB, |
||||
| 270 | 26913461 |
2 | ||
Renal failure, Therapy interrupted, |
||||
TALAZOPARIB, |
||||
| 271 | 26913462 |
77 | 2 | |
Dialysis, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 272 | 26913468 |
US |
73 | 2 |
Memory impairment, Balance disorder, Product use issue, Therapy interrupted, |
||||
SOTAGLIFLOZIN, |
||||
| 273 | 26913525 |
US |
57 | 1 |
Aspiration, Respiratory tract irritation, Hypertension, Oxygen saturation decreased, Therapy interrupted, |
||||
BENRALIZUMAB, BENRALIZUMAB, |
||||
| 274 | 26913983 |
US |
26 | 1 |
Haematochezia, Abdominal pain upper, Therapy interrupted, Insurance issue, |
||||
RIFAXIMIN, |
||||
| 275 | 26914229 |
US |
51 | 1 |
Hospitalisation, Therapy interrupted, |
||||
RIFAXIMIN, |
||||
| 276 | 26914326 |
US |
42 | 2 |
Migraine, Therapy interrupted, |
||||
ERENUMAB-AOOE, |
||||
| 277 | 26914373 |
GB |
33 | |
Depression, Feeling hot, Heat stroke, Pain, Therapeutic response shortened, Exposure via skin contact, Accidental exposure to product, Product administration error, Wrong technique in product usage process, Product dose omission issue, Inappropriate schedule of product administration, Off label use, Therapy interrupted, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 278 | 26914389 |
GB |
71 | |
Renal stone removal, Therapy interrupted, Intentional dose omission, |
||||
INFLIXIMAB-DYYB, |
||||
| 279 | 26914550 |
CA |
38 | |
Crohn^s disease, General physical health deterioration, Therapy interrupted, Inappropriate schedule of product administration, Off label use, Overdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, LISDEXAMFETAMINE DIMESYLATE, |
||||
| 280 | 26916842 |
27 | 2 | |
Insurance issue, Therapy interrupted, Treatment failure, Gastrointestinal disorder, |
||||
TIRZEPATIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, INSULIN GLARGINE, |
||||
| 281 | 26917163 |
66 | 1 | |
Neuropathy peripheral, Therapy interrupted, |
||||
LENALIDOMIDE, DARATUMUMAB, |
||||
| 282 | 26917209 |
|||
Mood altered, Therapy interrupted, |
||||
TADALAFIL, |
||||
| 283 | 26917211 |
90 | 2 | |
Pneumonia, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 284 | 26917229 |
48 | 1 | |
Pneumonia, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 285 | 26917233 |
57 | 2 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 286 | 26917242 |
75 | 2 | |
Urinary tract infection, COVID-19, Pulmonary thrombosis, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 287 | 26919243 |
54 | 2 | |
Pneumonia, Atrial fibrillation, Therapy interrupted, |
||||
MAVACAMTEN, |
||||
| 288 | 26919244 |
25 | 1 | |
Ankylosing spondylitis, Fatigue, Therapy interrupted, |
||||
ETANERCEPT, GOLIMUMAB, |
||||
| 289 | 26919282 |
74 | 2 | |
Therapy interrupted, Hospitalisation, |
||||
LENALIDOMIDE, |
||||
| 290 | 26919284 |
53 | 2 | |
Hospitalisation, Therapy interrupted, |
||||
NINTEDANIB, |
||||
| 291 | 26925449 |
|||
Product label issue, Haemorrhage, Fear, Skin laceration, Haemorrhagic stroke, Therapy interrupted, Gait inability, Emotional disorder, Loss of personal independence in daily activities, Socioeconomic precarity, Product packaging issue, Product communication issue, |
||||
RIVAROXABAN, |
||||
| 292 | 26904552 |
US |
2 | |
Pneumonia, Fall, Joint injury, Hospitalisation, Blood pressure increased, Therapy interrupted, Insurance issue, |
||||
VOCLOSPORIN, VOCLOSPORIN, VOCLOSPORIN, |
||||
| 293 | 26904917 |
US |
2 | |
Multiple fractures, Therapy interrupted, |
||||
ROMOSOZUMAB-AQQG, |
||||
| 294 | 26905020 |
CO |
75 | 2 |
Cough, Influenza, Therapy interrupted, Product dispensing issue, Off label use, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, LOSARTAN, |
||||
| 295 | 26905467 |
AR |
52 | 1 |
Metastases to liver, Dandruff, Genital rash, Skin burning sensation, Eyelid rash, Scab, Dry skin, Rash, Dizziness, Acne, Pruritus, Fatigue, Blood magnesium decreased, Nausea, Skin fissures, Hypersensitivity, Asthenia, Alopecia, Pain in extremity, Therapy interrupted, Facial pain, Stoma site discomfort, Genital dryness, Feeling hot, Insomnia, |
||||
PANITUMUMAB, |
||||
| 296 | 26905714 |
US |
84 | 2 |
Fall, Dyspnoea, Confusional state, Chest pain, Delirium, Pulmonary oedema, Wheezing, Cough, Asthma, Dyspnoea, Sputum discoloured, Therapy interrupted, Asthenia, Fatigue, Oedema peripheral, Arthritis, Retinal disorder, Generalised oedema, Adverse drug reaction, Insomnia, Stasis dermatitis, |
||||
BENRALIZUMAB, BENRALIZUMAB, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, AMLODIPINE, APIXABAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AZELASTINE, BACLOFEN, |
||||
| 297 | 26905819 |
US |
70 | |
Fatigue, Hypersomnia, Pruritus, Therapy interrupted, |
||||
RESMETIROM, RESMETIROM, CETIRIZINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, TIRZEPATIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, REPAGLINIDE, PANTOPRAZOLE, LISINOPRIL, ROSUVASTATIN, |
||||
| 298 | 26905838 |
US |
36 | |
Diarrhoea, Abdominal pain upper, Abdominal pain, Therapy interrupted, |
||||
RESMETIROM, |
||||
| 299 | 26905861 |
US |
1 | |
Therapy interrupted, |
||||
TILDRAKIZUMAB-ASMN, |
||||
| 300 | 26906072 |
US |
2 | |
Alopecia, Therapy interrupted, |
||||
APREMILAST, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30